On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to David Chaplin, United Kingdom, for 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol (combretastatin A4 phosphate) for the treatment of anaplastic thyroid cancer.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
The sponsorship was transferred to Diamond BioPharm Limited, United Kingdom, in January 2013.
The sponsorship was transferred to Diamond ROC EOOD, Bulgaria, in March 2019.
The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.
This medicine is now known as fosbretabulin tromethamine.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in July 2021 on request of the Sponsor.
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol (fosbretabulin tromethamine)
Treatment of anaplastic thyroid cancer
|Orphan designation status||
|EU designation number||
|Date of designation||
Diamond Pharma Services Ireland Limited
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: